Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + cyclophosphamide + dexamethasone for newly diagnosed or progressive Waldenstrom macroglobulinemia
ChiCTR2200058236Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib, cyclophosphamide and dexamethasone in Waldenström macroglobulinemia (WM), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoints: Objective response rate and Progression-free survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
zanubrutinibcyclophosphamidedexamethasone
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on ChiCTR2200058236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058236.